Merck Debt to Equity Ratio 2010-2025 | MRK
Current and historical debt to equity ratio values for Merck (MRK) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Merck debt/equity for the three months ending March 31, 2025 was 0.69.
| Merck Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2025-03-31 |
$0.00B |
|
0.00 |
| 2024-12-31 |
$70.73B |
$46.37B |
1.53 |
| 2024-09-30 |
$72.97B |
$44.56B |
1.64 |
| 2024-06-30 |
$68.98B |
$43.65B |
1.58 |
| 2024-03-31 |
$65.43B |
$40.42B |
1.62 |
| 2023-12-31 |
$69.04B |
$37.64B |
1.83 |
| 2023-09-30 |
$65.43B |
$41.30B |
1.58 |
| 2023-06-30 |
$65.73B |
$38.74B |
1.70 |
| 2023-03-31 |
$60.89B |
$46.91B |
1.30 |
| 2022-12-31 |
$63.10B |
$46.06B |
1.37 |
| 2022-09-30 |
$62.56B |
$44.52B |
1.41 |
| 2022-06-30 |
$63.78B |
$43.32B |
1.47 |
| 2022-03-31 |
$65.72B |
$40.95B |
1.61 |
| 2021-12-31 |
$67.44B |
$38.26B |
1.76 |
| 2021-09-30 |
$57.63B |
$35.86B |
1.61 |
| 2021-06-30 |
$57.30B |
$33.39B |
1.72 |
| 2021-03-31 |
$63.81B |
$27.04B |
2.36 |
| 2020-12-31 |
$66.18B |
$25.40B |
2.61 |
| 2020-09-30 |
$60.53B |
$29.27B |
2.07 |
| 2020-06-30 |
$62.87B |
$27.74B |
2.27 |
| 2020-03-31 |
$58.61B |
$26.30B |
2.23 |
| 2019-12-31 |
$58.40B |
$26.00B |
2.25 |
| 2019-09-30 |
$56.41B |
$26.93B |
2.10 |
| 2019-06-30 |
$56.23B |
$27.74B |
2.03 |
| 2019-03-31 |
$54.68B |
$27.67B |
1.98 |
| 2018-12-31 |
$55.76B |
$26.88B |
2.07 |
| 2018-09-30 |
$52.47B |
$32.66B |
1.61 |
| 2018-06-30 |
$52.27B |
$32.77B |
1.60 |
| 2018-03-31 |
$52.14B |
$33.90B |
1.54 |
| 2017-12-31 |
$53.30B |
$34.57B |
1.54 |
| 2017-09-30 |
$53.18B |
$38.50B |
1.38 |
| 2017-06-30 |
$53.09B |
$39.71B |
1.34 |
| 2017-03-31 |
$56.47B |
$40.09B |
1.41 |
| 2016-12-31 |
$55.07B |
$40.31B |
1.37 |
| 2016-09-30 |
$54.38B |
$43.96B |
1.24 |
| 2016-06-30 |
$53.03B |
$43.45B |
1.22 |
| 2016-03-31 |
$54.85B |
$43.90B |
1.25 |
| 2015-12-31 |
$56.91B |
$44.77B |
1.27 |
| 2015-09-30 |
$55.55B |
$45.68B |
1.22 |
| 2015-06-30 |
$55.94B |
$46.64B |
1.20 |
| 2015-03-31 |
$60.43B |
$47.92B |
1.26 |
| 2014-12-31 |
$49.38B |
$48.79B |
1.01 |
| 2014-09-30 |
$56.45B |
$45.36B |
1.24 |
| 2014-06-30 |
$49.34B |
$48.52B |
1.02 |
| 2014-03-31 |
$55.90B |
$52.56B |
1.06 |
| 2013-12-31 |
$53.32B |
$52.33B |
1.02 |
| 2013-09-30 |
$56.41B |
$50.01B |
1.13 |
| 2013-06-30 |
$56.77B |
$50.11B |
1.13 |
| 2013-03-31 |
$50.59B |
$55.61B |
0.91 |
| 2012-12-31 |
$50.67B |
$55.46B |
0.91 |
| 2012-09-30 |
$48.09B |
$58.21B |
0.83 |
| 2012-06-30 |
$47.85B |
$57.67B |
0.83 |
| 2012-03-31 |
$48.20B |
$57.31B |
0.84 |
| 2011-12-31 |
$48.19B |
$56.94B |
0.85 |
| 2011-09-30 |
$48.94B |
$57.60B |
0.85 |
| 2011-06-30 |
$48.27B |
$57.92B |
0.83 |
| 2011-03-31 |
$49.03B |
$56.84B |
0.86 |
| 2010-12-31 |
$48.98B |
$56.81B |
0.86 |
| 2010-09-30 |
$49.79B |
$58.05B |
0.86 |
| 2010-06-30 |
$48.51B |
$57.67B |
0.84 |
| 2010-03-31 |
$51.25B |
$60.34B |
0.85 |
| 2009-12-31 |
$50.83B |
$61.49B |
0.83 |
| 2009-09-30 |
$23.39B |
$25.35B |
0.92 |
| 2009-06-30 |
$26.67B |
$22.74B |
1.17 |
| 2009-03-31 |
$24.54B |
$22.00B |
1.12 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$192.420B |
$64.168B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
